BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, January 20, 2026
Home » Topics » Disease categories and therapies » Cancer

Cancer
Cancer RSS Feed RSS

Cancer

Innocare Pharma divulges new CBLB inhibitors

Nov. 4, 2025
Beijing Innocare Pharma Tech Co. Ltd. has synthesized E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
Read More
Concept art for targeting cancer
Cancer

Astellas’ CRBN-based protein degrader inhibits KRAS G12D tumor growth

Nov. 4, 2025
No Comments
Researchers at Astellas Pharma Inc. have reported preclinical efficacy data of ASP-4396, a KRAS G12D degrader.
Read More
Acute myeloid leukemia
Immuno-oncology

Evaxion unveils EVX-04 for acute myeloid leukemia

Nov. 4, 2025
No Comments
Evaxion A/S has unveiled EVX-04, an AI-designed precision cancer vaccine candidate being developed for acute myeloid leukemia (AML).
Read More
Cancer

Covalent p53 activator shows activity in Y220C-mutant models

Nov. 4, 2025
No Comments
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Frontier Medicines Corp. presented a first-in-class covalent activator of p53 Y220C with high potency and selectivity in restoring p53 tumor suppressor function.
Read More
Immuno-oncology

Optimized arenaviruses with tumor-tropic mutations show preclinical activity

Nov. 4, 2025
No Comments
Oncolytic viruses are a potential therapeutic approach that uses viruses to selectively infect and kill cancer cells. In a new publication in Cell Reports Medicine, researchers from Heinrich-Heine-Universität Düsseldorf and Abalos Therapeutics GmbH show that tumor-tropic mutations in lymphocytic choriomeningitis virus (LCMV) enhance selective replication in cancer cells.
Read More

Stock turns sharply higher with Terns’ leukemia data

Nov. 3, 2025
By Lee Landenberger
No Comments
Early stage data from Terns Pharmaceuticals Inc.’s lead candidate showed a large reduction in the number of leukemia cells in those with previously treated chronic myeloid leukemia. Results from the ongoing phase I Cardinal study of TERN-701, an oral, allosteric BCR-ABL tyrosine kinase inhibitor, were “unprecedented,” according to Terns.
Read More
Cancer

New triazole compounds disclosed in Guangdong Yinzhu patent

Nov. 3, 2025
Guangdong Yinzhu Pharmaceutical Technology Co. Ltd. and Guangzhou Yinzhu Biomedical Technology Co. Ltd. have divulged triazole compounds reported to be useful for the treatment of cancer, psoriasis, rheumatoid arthritis and inflammatory bowel disease.
Read More
Cancer

Beijing Double-Crane Runchuang Technology describes new heterocyclic compounds

Nov. 3, 2025
Beijing Double-Crane Runchuang Technology Co. Ltd. has identified heterocyclic compounds reported to be useful for the treatment of cancer.
Read More
Cancer

Sunrise Oncology divulges new interaction inhibitors targeting KRAS mutations

Nov. 3, 2025
Sunrise Oncology (Hong Kong) Ltd. has synthesized molecular glues acting as GTPase KRAS (and/or its mutant)/RAF proto-oncogene serine/RAF1 interaction inhibitors reported to be useful for the treatment of cancer.
Read More
Antibody-drug conjugate illustration
Immuno-oncology

ADAM9-targeting DB-1317 exhibits efficacy against several solid tumors

Nov. 3, 2025
No Comments
ADAM9 (a disintegrin and metalloproteinase 9) is overexpressed in several gastrointestinal cancers, with expression levels correlating with suppressive tumor microenvironment, metastasis and poor prognosis. DB-1317, under development at Duality Biologics (Suzhou) Co. Ltd., is an ADAM9-targeting antibody-drug conjugate including a topoisomerase inhibitor payload P1003 at a drug-antibody ratio of 8.
Read More
Previous 1 2 … 44 45 46 47 48 49 50 51 52 … 4052 4053 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 20, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing